ABEMA Alone or in COMBO With MK-6482

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2020

Primary Completion Date

February 9, 2024

Study Completion Date

August 4, 2024

Conditions

Clear Cell Renal Cell Carcinoma

Interventions

DRUG

Abemaciclib

Tablet taken orally

DRUG

MK-6482

Tablet taken orally

Trial Locations (1)

Dana Farber Cancer Institute, Boston

All Listed Sponsors

collaborator

Eli Lilly and Company

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Dana-Farber Cancer Institute

OTHER

NCT04627064 - ABEMA Alone or in COMBO With MK-6482 | Biotech Hunter | Biotech Hunter